摘要
目的探讨运用REC IST标准评价食管癌新辅助化疗疗效的可行性。方法选择新辅助化疗食管癌患者。根据食管钡餐X线片显示病变长度,将食管病灶分为T1、T2、T3、T4期,CT扫描确定N、M分期。FLP方案化疗2个周期后,按照REC IST标准评价食管癌化疗疗效。结果68例患者中,Tl、T2、T3、T4期分别为2、31、24、11例,N0、N1期分别为12、56例。临床分期Ⅲ、Ⅳa及Ⅳb期分别为25、20、23例。化疗2个周期后评价疗效,CR 1例,PR 27例,SD 30例,PD 10例,RR为41%。结论RE-C IST标准能够评价食管癌新辅助化疗疗效,食管钡餐X线片显示病灶长度确定食管癌T分期,更适用于临床应用。
Aim To assess the feasibility of the response of neoadjuvant chemotherapy in esophageal cancer with RECIST criteria. Methods The esophageal cancer patients with neoadjuvant chemotherapy were selected. According to barium meal X -ray film,the primary lesion lengths in esophagus were divided into T1 ,T2 ,T3 and T4. The N and M stage was determined by CT scan. The response was evaluated according to RECIST criteria after 2 cycles of chemotherapy of FLP regimen. Results There were 2 cases for T1,31 cases for T2,24 cases for T3 and 11 cases for T4 and 12 for N0,56 for N1 among the 68 cases of patients. In clinical stage,there were 25 cases for 111,20 eases for IVa and 23 cases for IVb. The response was evaluated after 2 cycles of chemotherapy. There were CR 1 case, PR 27 cases, SD 30 cases and PD 10 cases. The RR was 41%. Conclusions The response of neoadjuvant chemotherapy in esophageal cancer could be assessed with RE- CIST criteria. The T stage of esophageal cancer according to barium meal X-ray film is more convenient for the clinical application.
出处
《安徽医药》
CAS
2009年第5期521-523,共3页
Anhui Medical and Pharmaceutical Journal
基金
安徽省自然科学基金重点项目(No05021002)
关键词
食管癌
临床分期
RECIST
新辅助化疗
esophageal cancer
RECIST
clinical stage
neoadjuvant chemotherapy
